La vendita allo scoperto per DiDi Global dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di DiDi Global. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

DiDi Global (OTC:DIDIY) Azioni, Report sulle vendite allo scoperto

DiDi Global Inc is a mobility technology platform that provides a range of mobility services as well as other services. It is building four key components of its platform that work together to improve the consumer experience: shared mobility; energy and vehicle services; electric mobility; and autonomous driving. It is a go-to brand in China for shared mobility, providing consumers with a range of safe, affordable, and convenient mobility services, including ride-hailing, taxi-hailing, chauffeur, hitch, and other forms of shared mobility. The company operates in three segments: China Mobility, which mainly includes ride-hailing services to riders, and also acts as an agent by connecting end-users to service providers who provide taxi hailing; International; and Other Initiatives.

DIDI GLOBAL INC S/ADR by DiDi Global Inc.

DiDi Global Inc

Article via <a href="https://elplanteo.com/mercado-de-cannabis-en-puerto-rico-entrevista-prich/">El Planteo</a>
"Puerto Rico is a paradise for a cannabis entrepreneur," says Jaime Rengifo, CEO of <a href="https://elplanteo.com/prich/">Prich Biotech</a>, often regarded as the largest <a href="https://www.benzinga.com/money/best-latin-american-cannabis-companies">cannabis company in Latin America</a>. Since his arrival on the island, Rengifo has closely observed how this relatively small region has become a Latin American leader in <a href="https://elplanteo.com/cannabis-medicinal/">medicinal cannabis</a>, with a local market now surpassing $250 million annually. For Rengifo, however, success isn't just about numbers, it's about the model, education and accessibility that have fostered sustained growth and elevated product quality.
Watch the full episode of <a href="https://www.youtube.com/live/TzYjAsaQiFc?si=Tk6kE5Vi-nmyw980">&#8220;El Planteo Live&#8221;</a> on <a href="https://www.youtube.com/live/TzYjAsaQiFc?si=Tk6kE5Vi-nmyw980">YouTube</a>.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="El DIAMANTE EN BRUTO del CANNABIS LATINO: el SECRETO de PUERTO RICO" width="500" height="281" src="https://www.youtube.com/embed/TzYjAsaQiFc?start=1200&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Rengifo attributes Puerto Rico's progress in <a href="https://www.benzinga.com/cannabis">medicinal cannabis</a> to a functional regulatory system that allows patients to acquire medical marijuana from dispensaries located throughout the island. "People have access, patients can access products, in various formulations, various formats," he explains, referring to the range of consumption options available in Puerto Rico, which includes capsules, concentrates, <a href="https://elplanteo.com/comestibles-de-marihuana-guia-para-su-consumo/">edibles</a>, oils and even transdermal patches. While smoking cannabis is prohibited, the law allows for <a href="https://www.benzinga.com/topic/vaping">vaping</a>, an adjustment he believes has attracted a broader, more responsible consumer base.
See also: <a href="https://www.benzinga.com/markets/cannabis/23/09/33840003/latin-americas-best-kept-cannabis-secret-meet-the-biggest-marijuana-company-in-the-region">Latin America&#8217;s Best-Kept Cannabis Secret: Meet The Biggest Marijuana Company In The Region</a>
<h2 class="wp-block-heading">Education And Accessibility: Puerto Rico's Formula For Effective Medicinal Cannabis</h2>
For Rengifo, Puerto Rico's real triumph isn't just having an industry that works, but in how it works. He says the key lies in education and ensuring that access to medicinal cannabis is a right, not a privilege.
As CEO of Prich Biotech, Rengifo has championed educational programs to help both patients and doctors understand the benefits and correct use of the plant. "I don't see a reason why we should charge for a license [medical marijuana card] to obtain cannabis products," he says, adding that the system should ease access to treatments rather than complicate it with fees or unnecessary restrictions. "I believe cannabis is a therapeutic product."
Looking toward 2025, Rengifo and his team at Prich Biotech aim to further expand the reach of medicinal cannabis in Puerto Rico, particularly among senior citizens and military veterans &#8211; two groups he says could greatly benefit from the market. Just last week, Prich Biotech hosted an event targeting the baby boomer community. He said a surprising number of seniors not only showed interest in cannabis but were already familiar with its benefits.
"I really thought seniors would have a cultural barrier against cannabis," he admits. Yet the response was so positive that Prich Biotech is already planning a large-scale educational campaign for 2025 to reach more patients and reduce the stigma around medicinal cannabis use.
<h2 class="wp-block-heading">Challenges And Opportunities In A Responsibly Growing Cannabis Market </h2>
Rengifo recognizes that maintaining a competitive industry requires not only investment but ongoing adaptation. In Puerto Rico, he notes, cannabis initially had high prices, due partly to the early costly business models. However, as the market has matured, prices have dropped and the range of offerings has diversified. For him, this is crucial to popularize medicinal cannabis. "I can't keep prices high if I want to expand the industry and transform it," he explains.
Part of Rengifo&#8217;s strategy has been to optimize all cultivation and production processes at Prich Biotech. "We've automated production, standardized our cultivation processes," he says. Today, Prich Biotech can produce more grams of cannabis per square foot, maintaining consistent quality levels of <a href="https://elplanteo.com/que-es-el-thc/">THC</a> and <a href="https://elplanteo.com/que-es-el-cbd/">CBD</a>, making them, as he puts it, "very competitive in the market."
<h2 class="wp-block-heading">Puerto Rico's Potential: Preparing For A Cannabis Export Scenario</h2>
Rengifo envisions Puerto Rico not only as a regional model but as a potential benchmark for the global medicinal cannabis industry. The island, located about 1,000 miles southeast of Miami, Florida, boasts a historical pharmaceutical presence and robust infrastructure, which he believes could underpin the cannabis industry if U.S. laws move toward rescheduling or descheduling the plant at the federal level.
"We are preparing for the future," he says, noting that Prich Biotech is investing in Good Manufacturing Practices (GMP) certifications and standards that could allow it to export to markets like Europe and the United States.
"Puerto Rico is an island where all major pharmaceutical companies have a production facility… and cannabis, too, will become a valuable resource for Puerto Rico," Rengifo emphasizes. With a regulatory framework that models pharmaceutical quality standards, Puerto Rico, a US territory, could emerge as a leader in exporting medicinal cannabis—a goal Rengifo and his team are set on achieving.
Rengifo's vision, combined with Prich Biotech's focus on accessibility, education and efficiency paints a promising picture for Puerto Rico's medicinal cannabis industry. "This is a diamond in the rough," he says, and the journey is just beginning.
Cover image made with AI.

Cannabis

Latin America

News

Interview

'Diamond In The Rough' Of Latin American Cannabis: Puerto Rico's Success Secret Explained

Raymond James analyst Brian Vaccaro maintains First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Strong Buy and raises the price target from $22 to $25.

Price Target

Analyst Ratings

FWRG

Raymond James Maintains Strong Buy on First Watch Restaurant Gr, Raises Price Target to $25

Citigroup analyst Fatima Boolani maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Buy and raises the price target from $150 to $157.

DDOG

Citigroup Maintains Buy on Datadog, Raises Price Target to $157

WIIM

NUTX

Nutex Health shares are trading higher after the company reported better-than-expected Q3 sales results.

Trading Ideas

TOST

Watching Toast; Shares See Volume To The Upside Amid Comments Live On CNBC From Josh Brown

Betting against Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and CEO Elon Musk might not be a successful strategy, as the world's richest man frequently proves triumphant with his <a href="https://www.benzinga.com/general/education/24/06/39547388/happy-birthday-elon-musk-53-facts-and-figures-about-tesla-spacex-ceo-on-his-53rd-birthday">various companies and ventures.</a>
Many people have bet against Musk and lost over the years, including billionaire Bill Gates. Here's a look back at Gates' infamous short bet against Tesla and how much investors could have made betting on Musk instead.
What Happened: Tesla stock is up 30% over the last week, helped by Donald Trump's win in the 2024 presidential election and the belief that the new president will be good for <a href="https://www.benzinga.com/markets/equities/24/11/41832876/elon-musk-shines-in-trump-sweepstakes-a-big-win-for-tesla-dan-ives-thinks-so">Musk and the company.</a>
With Musk endorsing Trump for the 2024 election and campaigning for him, the billionaire will now turn his attention to helping work on government efficiencies under the new president.
Musk's new role could lead more people to bet against him, with some put off by his political leanings and others speculating that his time commitment to Trump could impact Tesla.
Past history shows that betting against Musk hasn't yielded good results for many.
One person betting against Musk was revealed to be Microsoft co-founder Gates. In a February appearance on the "Joe Rogan Experience" podcast, Musk revealed that he believed Gates had a short position on Tesla stock.
"I also heard that at one point he had a large short position. I don't know if that's true or not, but it seems weird. People I know who know the situation pretty well, I asked them ‘are you sure?' and they said &#8216;yes,&nbsp;he has a huge short position on Tesla.&#8217;&nbsp;That didn't work out too well," Musk&nbsp;<a href="https://open.spotify.com/episode/2aB2swgyXqbFA06AxPlFmr" target="_blank" rel="noreferrer noopener">told&nbsp;</a>Joe Rogan.
Shortly after the comments from Musk, Gates was&nbsp;<a href="https://www.cnbc.com/video/2021/02/18/bill-gates-tesla-elon-musk-green-economy.html" target="_blank" rel="noreferrer noopener">interviewed&nbsp;</a>by CNBC's&nbsp;Andrew Ross Sorkin.
"What Elon's done with Tesla is fantastic," Gates said. "We need more Elon Musks."
Gates was asked directly if he was short Tesla stock.
"I don't talk about my investments," Gates replied, failing to deny the accusation.
In April 2022,&nbsp;<a href="https://www.benzinga.com/news/22/04/26775590/leaked-chats-show-musk-confronted-bill-gates-about-shorting-tesla-heres-what-they-discussed" target="_blank" rel="noreferrer noopener">leaked texts between Gates and Musk</a>&nbsp;revealed that Gates was still short the stock. Ahead of a proposed meeting between the two billionaires, Musk asked Gates via text if he still held a short position on Tesla.
"Sorry to say I haven't closed it out," Gates said. "I would like to discuss philanthropy possibilities."
Musk&#8217;s reply to Gates was straightforward and sharp.&nbsp;"Sorry, But I cannot take your philanthropy on climate change seriously when you have a massive, short position against Tesla, the company doing the most to solve climate change."
Musk told a user on Twitter that the texts were real.
Gates has praised Musk for what he has done for electric vehicles but has also said that more should be done for other clean energy initiatives.
"It's important to say that what Elon did with Tesla is one of the greatest contributions to climate change anyone's ever made. And you know, underestimating Elon is not a good idea," Gates&nbsp;<a href="https://www.nytimes.com/2021/02/15/opinion/sway-kara-swisher-bill-gates.html?showTranscript=1" target="_blank" rel="noreferrer noopener">told&nbsp;</a>the New York Times.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Investing $1,000 in Tesla Stock:&nbsp;The comments by Gates on CNBC and the leaked texts, which Musk confirmed to be real, highlight that Gates likely was short Tesla stock.
The big questions are: When did Gates go short on Tesla, and is he still short?
Short sellers of Tesla in 2022&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/12/30186916/tesla-short-sellers-have-15b-in-2022-profits-and-they-are-still-piling-on" target="_blank" rel="noreferrer noopener">enjoyed strong returns,</a>&nbsp;with shares down over 60% on the year. Musk once estimated that Gates would need $1.5 billion to $2 billion to close out his $500 million short bet on Tesla.
Using the appearance on the Joe Rogan Experience podcast as a starting point, investors could have seen an opportunity to bet with Musk and Tesla and go against Gates being short.
An investor could have purchased 3.74 shares of Tesla at the time with $1,000 based on a split-adjusted price of $267.09. The $1,000 investment would be worth $1,190.07 today, based on a price of $318.20 for Tesla at the time of writing.
While the 19.0% hypothetical return seems mild, it could have been much better for investors who properly timed their trades.
The $1,000 investment from February 2021 would have been worth $1,533.29 in November 2021, up 53.3%, when Tesla hit all-time highs.
Tesla stock traded between $24.08 and $235.22 in 2020, a year that could have seen Gates initiate his short position. The average share price for Tesla was a split-adjusted $96.67.
Investors who put $1,000 into Tesla in 2020 when Gates may have initiated his short position could have bought 10.34 shares based on the yearly average. The same $1,000 investment would be worth $3,290.19 today, up 229%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/11/41752565/if-you-invested-1-000-in-tesla-stock-the-first-time-elon-musk-was-on-the-joe-rogan-podcast-here">If You Invested $1,000 In Tesla Stock The First Time Elon Musk Was On The Joe Rogan Podcast, Here&#8217;s How Much You&#8217;d Have Now</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
Image created with photos from Shutterstock.

Education

TSLA

If You Invested $1,000 In Tesla Stock When Bill Gates Shorted The Stock, Here's How Much You'd Have Today

APYX

Apyx Medical shares are trading higher after the company reported better-than-expected Q3 financial results. The stock initially traded lower, but it has since reversed.

Citigroup analyst Steven Zaccone maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Neutral and lowers the price target from $140 to $134.

Citigroup Maintains Neutral on Williams-Sonoma, Lowers Price Target to $134

RBC Capital analyst Conor McNamara maintains Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) with a Outperform and lowers the price target from $17 to $13.

MRVI

RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $13

Raymond James analyst Michael Rose maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Outperform and raises the price target from $19 to $22.

Raymond James Maintains Outperform on First Horizon, Raises Price Target to $22

Raymond James analyst Brian Peterson reiterates Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) with a Outperform and raises the price target from $37 to $65.

Reiteration

DOCS

Raymond James Reiterates Outperform on Doximity, Raises Price Target to $65

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has risen 6.9% since its last report. The company recently reported that it has 1.54 million shares sold short, which is 2.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731087922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into West Pharmaceutical Servs's Recent Short Interest

ASRT

Assertio Holdings shares are trading lower. Buxton Helmsley issued a letter to the companies shareholders disclosing its short position.

Chipotle Mexican Grill's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) short percent of float has fallen 3.93% since its last report. The company recently reported that it has 29.94 million shares sold short, which is 2.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Chipotle Mexican Grill Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731087917_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Chipotle Mexican Grill has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Chipotle Mexican Grill's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Chipotle Mexican Grill's peer group average for short interest as a percentage of float is 11.30%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Chipotle Mexican Grill?

Citigroup analyst Steven Zaccone maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Buy and lowers the price target from $115 to $109.

Citigroup Maintains Buy on Best Buy Co, Lowers Price Target to $109

Uranium Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UEC#NYSE">UEC</a>) short percent of float has fallen 3.53% since its last report. The company recently reported that it has 55.04 million shares sold short, which is 13.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Uranium Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731087912_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Uranium Energy has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Uranium Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Uranium Energy's peer group average for short interest as a percentage of float is 6.81%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Uranium Energy's Recent Short Interest

Raymond James analyst Steven Seedhouse maintains Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) with a Outperform and raises the price target from $51 to $56.

Comments

DiDi Global

Vendite allo scoperto

DiDi Global (OTC:DIDIY) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO